Prevalence of Skin Disorders in Sari, 2003-2004

    Zohreh Hajheydari, Monireh Golpour
    TLDR Skin disorders in Sari differ from other parts of Iran, with acne and hair loss being most common.
    The study conducted in Sari, Mazandaran, Iran, during 2003-2004, assessed the prevalence of skin diseases among 4,460 patients at Boo-Ali Sina hospital. The mean age of participants was 28.01 years, with 40.4% men and 59.7% women. The most common skin disorder observed was appendices disorders, primarily acne (55.8%) and androgenic alopecia (30%). Infections and dermatitis were the second and third most common issues, respectively, with irritant contact dermatitis being the most prevalent form of dermatitis. The study concluded that the prevalence and distribution of skin disorders in Sari differed from other regions in Iran, highlighting the need for further research to identify common skin disorders across the country.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community "DHT Itch" and onset Seborrheic Dermatitis

      in Research/Science  76 upvotes 2 years ago
      The post and conversation discuss the link between DHT (a hormone), scalp itchiness, and hair loss. Some users share their experiences and treatments, including the use of fluconazole, corticosteroids, and ketoconazole shampoo, with one user suspecting minoxidil as a potential cause of their symptoms.
      If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      in Research  830 upvotes 1 year ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
      The story of RU58841/ PSK3841

      community The story of RU58841/ PSK3841

      in Research  622 upvotes 1 year ago
      RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

    Similar Research

    6 / 1000+ results